Please ensure Javascript is enabled for purposes of website accessibility

Have You Sold Your Procter & Gamble Shares Yet?

By Matt Koppenheffer – Updated Apr 6, 2017 at 12:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Procter & Gamble reported earnings that disappointed the market.

The market voted yesterday, and the obvious verdict was that it's time to sell Procter & Gamble (NYSE: PG). Year over year, the bottom line was down 12% for the quarter, and sales, general, and administrative expenses went through the roof. The outlook was disappointing. Consumers are treading water. Everything is terrible.

Sell, sell, sell!

Relax, Fool. I'm kidding.

The 3.4% drop in P&G's shares yesterday certainly suggests that some investors were pretty unhappy with the earnings report. And to be sure, it's not ideal to see profits drop -- even if they were down a more palatable 6% when you exclude discontinued operations. But P&G isn't a company that warrants quarter-to-quarter reactions to a few pennies on earnings in either direction.

Zooming in
A closer look at the profit decline shows that it was driven by a near $1 billion ramp-up in SG&A -- much of it in marketing. P&G has been focused on expanding its opportunity in three primary ways: expanding its product portfolio to hit more value tiers, increasing its presence geographically, and improving existing products and moving into complementary categories. It shouldn't be all that shocking that succeeding in those goals would require some extra marketing muscle.

But the dip in P&G's stock also likely shows some of the same concerns that investors have had when it comes to competitors such as Clorox (NYSE: CLX) and Colgate-Palmolive (NYSE: CL). Namely, that crunched consumers are opting for cheaper generic brands -- think mirra beauty products from Kroger (NYSE: KR) or CVS (NYSE: CVS) brand diapers -- over the more expensive branded names from P&G and its ilk.

Is that happening? Probably to some extent. Bloomberg recently published an article outlining what the author referred to as "the new abnormal," where consumers save money by buying generic-brand necessities only to splurge on things like iPads. But I have trouble seeing that being a broad, sustained trend that will legitimately threaten P&G. I'll change my mind when consumers start trading down Coke and Pepsi for RC Cola en masse.

Time to buy?
Analysts currently expect that P&G will grow earnings around 8.5% per year over the next five years. To hit that target, the company will have to see some growth acceleration -- fiscal 2010 growth was 6% and the company expects an 8% bump in 2011. Success in the company's growth road map could provide that extra boost, as would continued improvement in the global economy.

At that rate of growth, P&G's stock looks to be priced pretty fairly today -- not cheap, but not particularly expensive either. It's not a stock that'll likely knock anyone's socks off, but for those looking for some stability and a dividend yield that beats Treasuries, it could be a decent choice.

With a high-quality portfolio of brands, P&G falls into a category of company that both Warren Buffett and I are big fans of.

Clorox and Procter & Gamble are Motley Fool Income Investor selections. The Fool owns shares of and has written covered calls on Procter & Gamble. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Matt Koppenheffer does not own shares of any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy assures you no Wookiees were harmed in the making of this article.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Procter & Gamble Company Stock Quote
The Procter & Gamble Company
PG
$135.58 (-0.46%) $0.63
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
The Kroger Co. Stock Quote
The Kroger Co.
KR
$44.86 (-1.41%) $0.64
Colgate-Palmolive Company Stock Quote
Colgate-Palmolive Company
CL
$75.53 (0.23%) $0.17
The Clorox Company Stock Quote
The Clorox Company
CLX
$141.58 (0.21%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.